Consumer Product Safety Improvement Act (CPSIA) Certifications
The Consumer Product Safety Improvement Act of 2008 (CPSIA) requires manufacturers to provide additional information on the child-resistant packaging of certain pharmaceuticals sold in the United States. More information about the details of this new law and its implementation may be found on the U.S. Consumer Product Safety Commission website.
The following is a list of prescription products that are distributed by Harris Pharmaceutical, Inc. which are subject to the provisions of CPSIA. In accordance with requirements for assuring that each product listed below complies with the Child-Resistance Packaging requirements, the design of the packaging was tested as indicated in each product certificate of compliance.
|NDC# (67405 -)||Product Name||Product Strength||Package Size|
|575-10||HydrOXYzine HCl Tablets||10 mg||100||PDF LINK|
|575-50||HydrOXYzine HCl Tablets||10 mg||500||PDF LINK|
|575-96||HydrOXYzine HCl Tablets||10 mg||1000||PDF LINK|
|671-10||HydrOXYzine HCl Tablets||25 mg||100||PDF LINK|
|671-50||HydrOXYzine HCl Tablets||25 mg||500||PDF LINK|
|671-96||HydrOXYzine HCl Tablets||25 mg||1000||PDF LINK|
|577-10||HydrOXYzine HCl Tablets||50 mg||100||PDF LINK|
|577-50||HydrOXYzine HCl Tablets||50 mg||500||PDF LINK|
|543-03||Terbinafine HCl Tablets||250mg||30||PDF LINK|
|543-10||Terbinafine HCl Tablets||250mg||100||PDF LINK|